Creatine (N-(aminoiminomethyl)-N-methyl glycine) is an ingredient commonly found in food, mainly in fish and meat, and is sold as a dietary supplement in markets around the world. Its use as an ergogenic aid and possible treatment for certain neuromuscular disorders is well documented in scientific literature (Buford et al. 2007; Kreider et al. 2010). In recent years, the popularity of creatine has risen dramatically, especially among athletes. In the USA alone, creatine-containing dietary supplements make up a large portion of the estimated $2.7 billion in annual sales of sports nutrition supplements (NBJ 2009).

Accompanying this explosive growth in sales has been the introduction of different forms of creatine. Creatine monohydrate (CM), first marketed in the early 1990s, is the form most commonly found in dietary supplement/food products and most frequently cited in scientific literature. The introduction into the marketplace of alternate forms of creatine, beginning in the late 1990s, was presumably an attempt to differentiate the multitude of creatine-containing products available to consumers and improve certain attributes such as solubility and efficacy. However, the legal and regulatory status of these various forms of creatine in the USA and other markets around the world is at best uncertain. To date, with the exception of Japan, CM is the only form of creatine to be officially approved or accepted in key markets such as the USA, European Union (EU), Canada and South Korea. The continued presence of other forms of creatine in the marketplace, especially in the US, may be due to a multitude of factors. These include, but may not be limited to, a lack of awareness or understanding on the part of marketers of applicable laws and regulations, intentional noncompliance with the law, and/or inadequate enforcement of the law. The public health implications of widespread distribution and use of these unauthorized forms of creatine is unknown and warrants careful monitoring.

New forms of creatine are marketed with claims of improved physical, chemical, and physiological properties in comparison to CM. Claims include improved stability when combined with other ingredients or in liquids, improved solubility in water, improved bioavailability, and even an increase in performance. This review will evaluate the available literature on new forms of creatine and compare them to available data on CM in terms of efficacy and safety. In addition, the current international regulatory status of the various forms of creatine that are commercially available will be examined.


This analysis represents a systematic review of the literature on the various forms of creatine available in the global marketplace as dietary supplements, food supplements, or natural health products. For technical and performance comparisons, literature searches were performed by searching the Medline database of the US National Library of Medicine of the National Institutes of Health. The search strategy involved entering the various creatine search terms (Table 1), along with the technical or performance aspect of interest (e.g., solubility, stability, bioavailability, performance). In addition, a patent research was performed by searching the database of the World Intellectual Property Organization (WIPO), the European Patent Office, the Japan Patent Office, and the United States Patent and Trademark Office. Articles were reviewed, analyzed, and interpreted, with results of the relevant studies presented below.

Table 1 Creatine content of different forms of creatine

For the assessment of the current regulatory status of the various forms of creatine, the Web sites of regulatory bodies for key markets around the world were accessed (USA: US Food and Drug Administration; Canada: Health Canada; EU: European Commission; Japan: Ministry of Health, Labor and Welfare; Korea: Korea Food and Drug Administration). Information derived from these sites was used to determine the legal and regulatory framework governing creatine products in these markets and the current regulatory status of the various forms of creatine as dietary supplements, food supplements, and natural health products.

Physio-chemical properties

Creatine crystallizes from water as monoclinic prisms holding one molecule of water of crystallization per molecule of creatine. Continued drying of CM results in a loss of the water of crystallization at around 100°C, yielding anhydrous creatine. Creatine is a weak base with a pkb value of 11.02 at 25°C. As a result, creatine can only form salts with strong acids, having a pka value of less than 3.98. Creatine forms salts by the protonation of its guanidine moiety (see Fig. 1). In addition to salt formation, creatine is able to act as a complexing agent.

Fig. 1
figure 1

Creatine salts

Creatine salts such as citrate, maleate, fumarate, tartrate (Negrisoli and Del Corona 1997), pyruvate (Pischel and Weiss 1996), ascorbate (Pischel et al. 1999), and orotate (Abraham and Jiang 2005) were first introduced to the marketplace as early as the late 1990s. Creatine and acids with multiple acid moieties such as citric acid can form salts as well as complexation products. The first acid moiety of citric acid is strong enough (pka = 3.09) to form a salt with creatine; however, the other two moieties (pka2 = 4.75, pka3 = 5.41) should only be able to form complexes with creatine. A salt, a salt-complex combination, or a simple physical mixture can be differentiated by measurement of the enthalpy changes of neutralization, which ranges usually in the area of −55 to −66 kJ/mole for the salt formation to less than −5 kJ/mole for the change in complexation enthalpy to no changes in enthalpy for a physical mixture (1995). A “tricreatine citrate” is actually a complex of creatine citrate with two additional creatine moieties, resulting in a molecule with a ratio of creatine to citrate of 3:1.

In addition to creatine and its salts, derivatives of creatine such as creatine ester or even creatine alcohols are currently marketed as dietary supplements in the USA (see Fig. 2). Both ingredients do not contain creatine as such, since they have been chemically altered. While it is assumed that the human body will transfer those molecules into creatine upon intake, there are no published data available to base firm conclusions.

Fig. 2
figure 2

Chemical structure of creatine and creatine derivatives

The amount of creatine in different forms of creatine varies. Creatine monohydrate contains 87.9% of creatine, whereas the creatine content in other forms of creatine is lower with the exception of creatine anhydrous (see Table 1). Commercial creatine salts are formed in solution or by mechanical processes such as milling or grinding under the presence of residual water. Complexes are formed by the subsequent replacement of the solvating molecules by the new ligands.


One major limitation of creatine as an ampholytic amino acid is its rather low solubility in water. The solubility of creatine in water increases with temperature and the correlation between solubility and temperature is almost linear. One liter of water dissolves 6 g of creatine at 4°C, 14 g at 20°C, 34 g at 50°C, and 45 g at 60°C. The solubility of creatine can also be increased by lowering the pH of the solution. This principle is the basis for the improved solubility of creatine salts, since creatine salts lower the pH of water due to the nature of acid moiety. Creatine monohydrate dissolves at 14 g/L at 20°C resulting in a neutral pH of 7. A saturated solution of tricreatine citrate in water has a pH of 3.2; whereas a saturated solution of creatine pyruvate even has a pH of 2.6 (pyruvic acid is a stronger acid than citric acid). The decrease in pH results in an increase in solubility: 29 g/L creatine citrate at 20°C, and 54 g/L creatine pyruvate at 20°C. Normalized by the relative amount of creatine per molecule (monohydrate 87.9%, citrate 66%, pyruvate 60%), creatine citrate (19.14 g/L) shows a 1.55-fold and creatine pyruvate (32.4 g/L) a 2.63-fold better solubility when compared with the monohydrate (12.3 g/L). Whereas the creatine derivative creatinol-O-phosphate (5 g/L at 20°C) has inferior solubility, dicreatinol sulfate (1,370 g/L at 20°C) shows superior solubility when compared with CM, creatine salts, or creatine esters (Godfraind et al. 1983; Gastner et al. 2005).


Stability in solid form

Creatine monohydrate powder is very stable showing no signs of degradation over years, even at elevated temperatures. To detect a potential degradation of creatine, one must measure the content of its degradation product, creatinine (see Fig. 3), which can be quantified by HPLC at levels as low as 67 parts per million (ppm). At room temperature and even at an increased temperature of 40°C (104°F), CM shows no signs of degradation (i.e., creatinine levels stay under the quantification limit of 67 ppm) after more than 3 years. As Fig. 3 shows, even when stored at 60°C (140°F), creatinine (106 ppm) was only detected after a period of 44 months (Jäger 2003).

Fig. 3
figure 3

Stability of creatine monohydrate powder. Adapted from Jäger (2003)

Stability in solutions

As shown in Fig. 4, in contrast to its stability in a solid state, creatine is not stable in aqueous solution due to an intramolecular cyclization (Howard and Harris 1999). The rate of creatine degradation in solution is not dependent on its concentration, but on pH. Generally, the lower the pH and higher the temperature, the faster is the degradation. This solid-state and degradation properties have been thoroughly investigated as early as the 1920s (Edgar and Shiver 1925; Cannon et al. 1990) and more recently by Dash et al. (2002), as well as Harris et al. (Howard and Harris 1999). These researchers found that whereas creatine was relatively stable in solution at neutral pH (7.5 or 6.5), a lowering of pH resulted in an increased rate of degradation and after only 3 days of storage at 25°C creatine degraded significantly: 4% at pH 5.5; 12% at pH 4.5; and 21% at pH 3.5 (see Fig. 5). Similarly, Ganguly et al. (2003) reported that creatine monohydrate stored at room temperature degraded into creatinine within several days but that refrigerating creatine monohydrate in solution slowed degradation. The rapid degradation of creatine in solution precludes the manufacture of shelf-stable standard acidic beverages containing efficacious amounts of the ingredient. If creatine is not consumed immediately after it has been dissolved in water, it should be stored at a low temperature to retard the degradation.

Fig. 4
figure 4

Degradation of creatine to creatinine

Fig. 5
figure 5

Effect of pH on creatine stability in solution. Adapted from Howard and Harris (1999)

The degradation of creatine can be reduced or even halted by either lowering the pH under 2.5 or increasing the pH. A very high pH results in the deprotonation of the acid group, thereby slowing down the degradation process by making it more difficult for the intramolecular cyclization. A very low pH results in the protonation of the amide function of the creatine molecule, thereby preventing the intramolecular cyclization (see Fig. 6). This effect also occurs under the acidic conditions in the stomach, hence preventing the breakdown of creatine. The conversion of creatine to creatinine in the gastrointestinal tract is minimal regardless of transit time (Persky et al. 2003; Harris et al. 1992b; Deldicque et al. 2008).

Fig. 6
figure 6

Very low pH prevents creatine degradation

Stability of other forms of creatine

Some creatine salts appear to be less stable when compared with CM. Tricreatine citrate results in creatinine levels of 770 ppm at 40°C (104°F) after 28 days of storage. However, the addition of carbohydrates has been shown to increase stability of some creatine salts (Purpura et al. 2005). Creatine salts are not expected to have a greater stability in solution; however, the pH lowering effect of the salt might reduce stability compared to CM in the same environment.

Tallon et al. (Child and Tallon 2007) compared the stability of creatine ethyl ester (CEE) head to head with CM and found that CEE was actually less stable than CM. It was concluded that the addition of the ethyl group to creatine actually reduced acid stability and accelerated its breakdown to creatinine. The degradation of creatine and creatine ester involves intramolecular hydrolysis of a carboxyl acid (in case of creatine) or carboxylic ester (in case of creatine methyl- or ethyl ester) under acidic conditions and the rate of degradation depends on the leaving group (see Fig. 7). It is speculated that the methyl ester or ethyl ester groups are better leaving groups than hydroxyl or water and, therefore, suggesting that the degradation into creatinine should be rather accelerated.

Fig. 7
figure 7

Degradation of creatine and creatine ester

These findings are also in accordance with the recent investigations on the stability of CEE at 37ºC in both water and phosphate-buffered saline and the in vitro response of CEE to incubation in human plasma by H-NMR analysis (Giese and Lecher 2009b). The conversion of CEE to creatine by the esterases in human plasma was not detected, and the only species detected after the incubation period was creatinine. It is concluded that CEE is mostly converted into creatinine under physiological conditions encountered during transit through the various tissues, suggesting no ergogenic effect is to be expected from supplementation of CEE. The high stability of CM is well documented, whereas the stability of newer forms of creatine (salts, ester, etc.) either has not been investigated or appears to be inferior. New forms of creatine contain less of the active principal creatine in comparison to CM; however, creatine salts can offer an advantage over CM with regard to solubility.


The uptake of creatine is simplified in a two-step approach: first, uptake into the blood stream; second, uptake into the target tissue. The term ‘bioavailability’ refers to both the intestinal absorption and the use of a substance by the body’s cells and tissues. First indications of a potential change of creatine bioavailability can be gathered from the amount of creatine taken up into the blood plasma after oral administration. However, a change in the total amount of creatine in the blood plasma cannot be directly extrapolated to a potential increase in desired performance. An increased amount of creatine in the plasma could be the result of decreased uptake into the target tissue resulting in an actual decrease in overall bioavailability. On the other hand, an initial rise in plasma creatine levels, followed by a reduction in plasma levels, is an indication of increased uptake into the target tissue. This has been demonstrated in vivo by combining creatine with insulin-stimulating ingredients such as high amounts of glucose or protein (Bessman and Mohan 1992; Haughland and Chang 1975; Rooney et al. 2002). Conclusive proof of an increase in relevant bioavailability can only be gained by assessing the amount of creatine reaching the target tissue, the muscle, measured by muscle biopsy and/or whole body creatine retention assessed by measuring the difference between creatine intake and urinary excretion.

Dietary creatine is presumed to have high bioavailability since intestinal absorption of CM is already close to 100% (Deldicque et al. 2008). However, the response to creatine supplementation is heterogeneous, due in part to some non-responders, which might be overcome by alternative forms of creatine (Greenhaff 1997b; Greenhaff et al. 1993). Several studies have examined whether different forms of creatine are more effective in terms of promoting muscle uptake of creatine than CM. For example, a recent study examined the effect of the administration of three different forms of creatine on plasma creatine concentrations and pharmacokinetics. In a balanced cross-over designed study, six healthy subjects were assigned to ingest a single dose of isomolar amounts of creatine (4.4 g) in the form of CM, tricreatine citrate (TCC), or creatine pyruvate (CPY), followed by measurement of the plasma creatine levels (Jäger et al. 2007). Mean peak concentrations and area under the curve (AUC) were significantly higher with CPY (17 and 14%, respectively) in comparison to CM. The findings suggest that different forms of creatine may result in slightly different kinetics of plasma creatine absorption, although differences in velocity constants of absorption could not be detected due to the small number of blood samples taken during the absorption phase. The small differences in kinetics are unlikely to have any clinically relevant effects on muscle creatine elevation during periods of creatine loading. A follow-up study including muscle biopsies would be required to conclude if the bioavailability of this specific creatine salt was indeed higher (Fig. 8).

Fig. 8
figure 8

Comparison of blood plasma levels of different forms of creatine. Adapted from Jäger et al. (2007)

Greenwood et al. (2003) investigated how different forms of creatine affect whole body creatine retention. Sixteen males were assigned to ingest in a single blind manner either 5 g of dextrose, 5 g of CM, 5 g of CM plus 18 g dextrose, or an effervescent creatine supplement consisting of 5 g of TCC (66% creatine) plus 18 g dextrose four times/day for 3 days. Creatine retention was estimated by subtracting total urinary creatine excretion from total supplemental creatine intake over the 3-day period. Results revealed that average daily creatine retention over the 3-day period was 12.2 ± 1.3, 16.1 ± 2.2, and 12.6 ± 2.5 g/day for the CM, CM with dextrose, and effervescent TCC groups, respectively. This amounted to whole body creatine retention of 61 ± 15% for the CM group, 80 ± 11% for the CM plus dextrose group, and 63 ± 13% for the effervescent TCC group. While creatine retention was significantly greater in the CM and dextrose group, no significant differences were seen between the CM and effervescent TCC groups. These findings suggest that while consuming a relatively small amount of dextrose with CM can increase whole body creatine retention, supplementation of TCC in an effervescent form does not augment whole body creatine retention more than CM alone (Fig. 9).

Fig. 9
figure 9

Percentage of creatine retained during a 3-day loading period (20 g/day). Adapted from Greenwood et al. (2003)

Over the years, there has been significant commercial interest in determining whether creatine could be delivered in a liquid form. The thought has been since CM is relatively insoluble that development of a liquid or suspended form of creatine may be more convenient to consume, be more readily absorbed into the blood stream, and promote a greater efficiency in transport of creatine to the muscle. Some companies have even claimed that minimal amounts of liquid creatine would need to be ingested because of enhanced efficiency in transport through the blood and into the muscle. A limitation with these theories is that CM is not stable for any substantial length of time in liquid. Consequently, while researchers have been working on ways to suspend creatine within gels and fluids, it has been generally considered to be impractical to develop into a product due to limitations in shelf-life. In addition, while people may prefer the taste of liquid or gel versions of creatine, there is no evidence that these delivery forms provide a superior performance benefit.

Kreider et al. (2003b) carefully compared the effects of ingesting 20 g/day of CM to recommended doses (2.5 g/day of CM), as well as doses that would purportedly provide an equivalent amount of CM per day in liquid form (20 g/day) on muscle creatine, phosphocreatine, and total creatine levels. Subjects donated muscle biopsies prior to and following 5 days of supplementing their diet in a randomized and double-blind manner with either 5 mL of creatine liquid (purportedly providing 2.5 g of CM), 5 mL of a flavored placebo, 8 × 5 mL doses of creatine liquid (purportedly providing 20 g/day of CM), or 8 × 5 mL doses of a flavored placebo. Another group ingested 4 × 5 g of CM for 5 days as a non-blinded benchmark control. This analysis allowed for a comparison of ingesting recommended doses of liquid creatine to a placebo, as well as seven times the amount recommended by the manufacturer that would purportedly provide an equal amount of CM. The researchers found that CM supplementation significantly increased muscle free creatine content by 31 ± 28%. However, none of the other groups experienced any effect on muscle free creatine, phosphocreatine, or total creatine content. Moreover, changes in muscle creatine and phosphocreatine levels in response to CM supplementation were significantly greater than the liquid creatine and placebo groups. These findings indicate that liquid creatine supplementation has no effect on muscle phosphagen levels and therefore may have no ergogenic value. While other groups have been attempting to develop stable forms of liquid and/or gel forms of creatine with some success, there are no data available to date demonstrating that these types of creatine are absorbed more efficiently and/or have greater benefit compared to CM (Fig. 10).

Fig. 10
figure 10

Change in muscle-free creatine content in response to 5 days of low or high-dose creatine serum and placebo ingestion compared to CM. Adapted from Kreider et al. (2003b)

An alternative dissolved form of creatine is colloidal CM. CM is dissolved in its own crystal water and dispersed into a stable protective matrix containing carbohydrates (Kessel et al. 2004). The product is claimed to be the only solubilized form of powdered creatine in the market, making it more bioavailable and stable. However, no evidence has been published to date to substantiate any performance or ergogenic benefit from this form of creatine.

Creatine ethyl ester has been purported to be a superior form of creatine in comparison to CM. However, prior studies have shown that it degrades rather quickly to creatinine when exposed to low pH levels as would be found in the stomach (Giese and Lecher 2009a; Katseres et al. 2009). Theoretically, this would reduce the bioavailability of creatine. To test this hypothesis, Spillane et al. (2009) compared the effects of supplementing the diet with a placebo, CM, or CEE during 42 days of training. Serum creatinine and muscle total creatine content was assessed prior to and following 6, 27, and 48 days of supplementation and training. The researchers found that serum creatinine levels were significantly increased in the CEE group after 6, 27, and 48 days of supplementation indicating less efficient bioavailability. In addition, while CEE supplementation promoted a modest increase in muscle total creatine content, it was increased to a greater extent in the CM group. These findings directly contradict claims that CEE is more effective in increasing muscle creatine stores. Further, the significantly higher creatinine levels observed should raise some potential safety concerns about potential safety (Fig. 11).

Fig. 11
figure 11

Changes in total muscle creatine content in response to placebo (PLA), creatine monohydrate (CRT), and creatine ethyl ester (CEE) supplementation (Spillane et al. 2009). Significantly different from PLA group. *Significant difference from baseline. Reprinted with permission

Several studies have also evaluated whether co-ingestion of creatine with other nutrients may influence creatine retention. Initial work by Green and colleagues (Green et al. 1996a, b) demonstrated that co-ingesting creatine (5 g) with large amounts of glucose (e.g., 95 g) enhanced creatine and carbohydrate storage in muscle. Subsequent studies by Steenge et al. (2000) found ingesting creatine (5 g) with 47–97 g of carbohydrate and 50 g of protein also enhanced creatine retention. The researchers suggested that creatine transport was mediated in part by glucose and insulin. As a result, additional research has been undertaken to assess the effect of co-ingesting creatine with nutrients that may enhance insulin sensitivity on creatine retention.

Several studies have examined whether co-ingesting creatine with d-pinitol influences whole body creatine retention. In the first study (Greenwood et al. 2001), 12 male subjects with no history of creatine supplementation donated 24-h urine samples for 4 days. After an initial control day designed to determine normal daily creatine excretion rates, subjects were then matched according to body mass and randomly assigned to ingest in a single-blind manner either a placebo (4 × 5 g doses of dextrose), CM (4 × 5 g), CM with low-dose d-pinitol (4 × 5 g CM with 2 × 0.5 g of d-pinitol), or CM with high-dose d-pinitol (4 × 5 g CM with 4 × 0.5 g d-pinitol) for 3 days. Whole body creatine retention was estimated by subtracting total urinary creatine excretion from total supplemental creatine intake over the 3-day period. Results revealed that whole body creatine retention over the 3-day loading period was significantly greater in the low-dose d-Pinitol group in comparison to the group ingesting CM alone. However, no differences were seen between CM alone and CM with the higher dose of d-Pinitol (Fig. 12).

Fig. 12
figure 12

Change in whole body creatine retention in response to 5 days of placebo, creatine monohydrate (CM), low-dose d-pinitol (P) and CM, and high-dose P and CM supplementation. Adapted from Kerksick et al. (2007)

In a follow-up study, Kerksick et al. (2009) examined whether co-ingestion of d-pinitol with CM would affect training adaptations, body composition, and/or whole-body creatine retention in resistance-trained males. In the study, 24 resistance trained males were randomly assigned in a double-blind manner to CM + d-pinitol or CM alone prior to beginning a supervised 4-week resistance training program. Subjects ingested a typical loading phase (i.e., 20 g/day for 5 days) before ingesting 5 g/day for the remaining 23 days. Results revealed that creatine retention increased in both groups as a result of supplementation. However, no significant differences were observed between groups in training adaptations. Consequently, additional research is needed to determine whether d-pinitol supplementation enhances creatine uptake and/or affects the ergogenicity of creatine supplementation before firm conclusions can be drawn.

Russian tarragon (Artemisia dracunculus) is an ethanolic extract that is often used as a cooking herb. Studies have shown that Russian tarragon (RT) appears to have antihyperglycemic activity when combined with CM ingestion (Jäger et al. 2008a; Wang et al. 2008). Theoretically, ingesting RT extract prior to creatine loading may enhance insulin sensitivity and thereby promote greater creatine absorption/retention. To support this hypothesis, Jäger et al. (2008a) reported that RT influences plasma creatine levels during the ingestion of CM in a similar manner to glucose and protein. However, further research is needed to evaluate the effects of RT on creatine uptake and retention in muscle before conclusions can be drawn (Fig. 13).

Fig. 13
figure 13

Influence of Russian tarragon on creatine absorption. Adapted from Jäger et al. (2008a)

In analysis of this literature, it is clear that CM supplementation promotes significant increases in muscle creatine levels in most individuals. There is some evidence that co-ingestion of CM with various nutrients (e.g., carbohydrate, protein, d-pinitol) may enhance creatine uptake to a greater degree. However, there is no evidence that effervescent creatine, liquid creatine, and/or CEE promotes greater uptake of creatine to the muscle. Rather, there is some evidence that some of these forms of creatine may be less effective and/or be of greater clinical concern in terms of safety.

Ergogenic properties

Creatine monohydrate

Numerous studies have found that CM supplementation increases muscle phosphagen levels generally by 10–40% (Greenhaff 1997a; Harris et al. 1992a; Hultman et al. 1996). Acute and chronic supplementation of CM has been reported to improve performance primarily during high intensity, intermittent activities (Greenhaff 1997a; Kraemer and Volek 1999; Kreider 2003). The impact on performance has been associated with the magnitude of change in baseline phosphagen levels (Burke et al. 2003a; Greenhaff 1997a). Numerous studies have shown that CM supplementation during training promotes greater gains in performance and/or fat-free mass (Cribb and Hayes 2006; Kreider et al. 1998; Volek et al. 1997, 1999; Willoughby and Rosene 2001; Willoughby and Rosene 2003). The only clinically significant side effect reported in literature has been weight gain, which is an attribute desired by many athletes who desire to increase muscle mass as well as clinical populations concerned about muscle wasting (Bender et al. 2008; Dalbo et al. 2008; Kreider et al. 2003a; Schilling et al. 2001). Consequently, CM has proven to be one of the most effective, safe, and well-studied ergogenic aids.

Creatine salts

Creatine has been combined with different organic acids to form creatine salts with the intention of using acids that will create a synergistic effect or simply improve the properties of creatine. A limitation of this approach is that effective daily doses of creatine and the acid will have to match to achieve meaningful physiological effects. In addition, creatine salts will have to outperform the physical mixture of CM and the corresponding acid, showing synergistic effects.

Inorganic salts of pyruvic acid have been shown to improve endurance when ingested in high amounts in rats (Ivy 1998), and consequently creatine has been combined with pyruvic acid to form creatine pyruvate (CPY), with the suggested benefit of a synergistic effect between the two. The potential endurance enhancing effects of CPY has been investigated in several studies, using doses of pyruvate significantly lower than previously found to be effective. Two studies investigating the endurance exercise capacity of short-term CPY supplementation showed mixed results. In this regard, 7 days of 7 g per day CPY supplementation did not beneficially impact endurance capacity or intermittent sprint performance in well-trained cyclists (Van Schuylenbergh et al. 2003), whereas 5 days of 7.5 g per day CPY intake increased paddling speed and resulted in decreased lactate concentrations in Olympic canoeists, suggesting an increase in aerobic metabolism (Nuuttilla 2000). A recent double-blind, placebo-controlled, randomized study evaluated the effect of oral CPY supplementation on exercise performance in healthy young athletes in comparison to placebo and TCC (Jäger et al. 2008b). It was concluded that 4 weeks of supplementation with creatine salts significantly improved performance during intermittent handgrip exercise of maximal intensity and that CPY might benefit endurance, due to enhanced aerobic metabolism. This study is a first indication that the creatine salt CPY may have potential advantage over CM. However, more research is needed to investigate this effect.

Creatine citrate (CC) has been used in several performance studies; however, none of those studies compared the product to CM. High-dose, short-term CC supplementation (4 × 5 g CC per day for 5 days) has been found to increase anaerobic working capacity (AWC) in healthy physically active women (Eckerson et al. 2004) and is able to delay the onset of neuromuscular fatigue during cycle ergometry (Smith et al. 2007). In a recent study, CC supplementation was able to raise the ventilatory threshold during intensity interval training (Graef et al. 2009). Although these studies are interesting, more research is needed particularly comparing CC to CM before it can be concluded that CC has any additional benefits.

Creatine ester

To date, Spillane et al. (2009) are the only group that has studied the impact of CEE supplementation on training adaptations in resistance trained individuals. The researchers randomly assigned in a double-blind manner 30 male resistance-trained athletes to ingest 0.30 g/kg per day fat-free mass (about 20 g/day) of either a placebo, CM, or CEE for 42 days. As stated previously, CEE supplementation did not promote greater total muscle creatine levels in comparison to placebo. In terms of training adaptations, CEE supplementation did not promote greater gains in body mass, fat-free mass, strength, or sprint performance. These findings indicate that CEE has no apparent ergogenic value over CM despite widespread claims that it is a more superior form of creatine. Additionally, the significantly higher creatinine levels observed indicate it is degraded to a greater degree and may pose greater safety concerns.


Creatinol in the form of creatinol-O-phosphate (COP) has been described and used in subjects with deficient myocardial circulation (Guglielmi and Mammarella 1979). Based on the findings that intravenous administration of COP in healthy human subjects led to increased values of creatinine in urine, it is speculated that creatinol acts as a precursor of creatine and is metabolized into creatine within the body (Melloni et al. 1979). The increased urinary values are derived from the degradation of creatine into creatinine through the typical biochemical pathways. Only one study investigated the ability of COP to improve muscular performance (Nicaise 1975). Fifty female patients were treated intramuscularly and intravenously with COP and performance tested utilizing a Martin Vigorimeter to measure muscle strength in both hands. The administration of COP resulted in a statistically significant improvement in hand strength.

Creatine-containing nutritional formulations

Since a number of studies have reported that CM supplementation can increase performance and/or training adaptations, there has been interest in determining whether ingesting creatine with other potentially ergogenic nutrients may affect performance and/or training adaptations to a greater degree. For example, studies have indicated that ingesting creatine with vitamin and mineral-fortified carbohydrate and protein supplements promote greater gains in strength and fat-free mass than carbohydrate or carbohydrate and protein supplements alone (Kreider et al. 1996, 1999; Cribb et al. 2007a; Kreider et al. 1998). Additionally, co-ingesting creatine with different types of protein may have differential effects on gains in fat-free mass and/or training adaptations (Kerksick et al. 2007; Cribb et al. 2007b). Several studies have also indicated that co-ingesting CM with other potentially ergogenic nutrients such as beta-hydroxy-beta-methylbutyrate (HMB) (Jowko et al. 2001), beta-alanine (Hoffman et al. 2006), phosphates (Eckerson et al. 2005), and alpha-lipoic acid (Burke et al. 2003b) may have some additive effects. While not all studies have reported statistically significant differences, these studies and others support contentions that including CM in nutritional formulations may promote additive and/or synergistic effects on training and/or performance.

Regulatory status


The legal and regulatory status of creatine forms other than CM in the USA, the largest market worldwide for dietary supplements, is somewhat ambiguous. According to US law, a “dietary supplement” is defined as “…a product (other than tobacco) intended to supplement the diet that bears or contains one or more of the following dietary ingredients: a vitamin; a mineral; an herb or other botanical; an amino acid; a dietary substance for use by man to supplement the diet by increasing the total dietary intake; or a concentrate, metabolite, constituent, extract…” (Federal Food, Drug and Cosmetic Act 1938a). Creatine, an amino acid derivative, would appear to satisfy this requirement. A “new dietary ingredient” (NDI) is defined as “…a dietary ingredient that was not marketed in the United States before October 15, 1994…” The law considers a dietary supplement that contains a new dietary ingredient adulterated, unless the ingredient has been present in the food supply as an article used for food in a form in which the food has not been chemically altered, or there is a history of safe use of the ingredient and that the ingredient is the subject of a 75-day premarket notification to the Food and Drug Administration (FDA) (Federal Food, Drug and Cosmetic Act 1938b). The requirement for the notification to FDA prior to entering the market is to demonstrate to the agency that the ingredient, as intended to be used, is reasonably expected to be safe.

The legal and regulatory status of CM is unequivocal. CM first appeared on the US market in 1993 (EAS 1993) and therefore is not an NDI and instead is considered “Grandfathered” (i.e., a dietary ingredient marketed in the USA prior to 15 October 1994). Furthermore, it satisfies the statutory requirement of having been present in the food supply in a form that has not been chemically altered. Since 1994, many new alternate forms of creatine have entered the US marketplace, and only several of these have been subjected to the requisite 75-day new dietary ingredient notification (NDIN) to FDA. These alternate forms of creatine include, but may not be limited to, CC, CEE, COP, CPY, creatine malate (CML), creatine phosphate (CP), creatine-l-carnitinate (CLC), and tricreatine orotate (TCO). Of these, only CEE, CPY, CLC and TCO have been the subject of an NDI to the FDA, submitted to the agency between 1998 and 2004 (FDA 1995). The FDA has objected to each notification (with the exception of CPY where no decision has yet been posted) citing one or more of the following reasons as the basis for their objection:

  1. 1.

    the form(s) of creatine may not be legal dietary ingredients as defined by the FD&C Act §201(ff);

  2. 2.

    inadequate information to conclude that the form(s) of creatine is reasonably expected to be safe due to insufficient safety data and/or failure to establish a history of safe use; and/or,

  3. 3.

    inadequate information about the chemical identity of the creatine form(s)

In each of its letters of objection, FDA includes the following text: “Therefore, your product may be adulterated under 21 U.S.C 342(f)(1)(B) as a dietary supplement that contains a new dietary ingredient for which there is inadequate information to provide reasonable assurance that such ingredient does not present a significant or unreasonable risk of illness or injury. Introduction of such a product into interstate commerce is prohibited under 21 U.S.C. 331(a) and (v)…

Due to the nature of the notification process in the USA, a non-response from FDA could, in theory, be considered a “non-objection” from the agency. Thus, the agency’s view on the regulatory status of CPY remains unclear. However, with the notification process, FDA maintains the right to object at any time, whether it has previously responded or not. Thus, with the exception of CM and perhaps CPY, other forms of creatine appear to be on the US market without the proper sanction from FDA or without notification to FDA altogether.


In Canada, creatine is considered a natural health product (NHP), the regulation of which is administered by the Natural Health Products Directorate (NHPD) of Health Canada (NHPD 2003). The NHP regulation requires that all NHP products be licensed and approved by the NHPD, and each is assigned an eight-digit numerical code. With respect to ingredients, the NHPD has developed a compendium of monographs as a tool to assist with the review of the safety and efficacy of many commonly used NHPs (NHPD 2007). This allows applicants to reference an NHPD monograph in support of their product license application and circumvents the need to evaluate ingredients already known to be safe and efficacious when used under the conditions specified in the NHPD monograph. For creatine, only CM has been approved for use in NHPs and was recently assigned a monograph by the NHPD (NHPD 2008). At present, there are 17 creatine-containing licensed and approved NHPs, all of which contain CM (NHPD 2010).

European Union

In the EU, creatine is regulated as a food supplement under the Food Supplement Directive (FSD) (EPC 2002) and the directive on substances that may be added for specific nutritional purposes in foods for particular nutritional uses (FPNU) (EPC 2001). In 2004, the European Food Safety Authority (EFSA) issued a positive opinion on CM for FPNU (EFSA 2004). No other opinions have been issued on any other creatine forms, either by EFSA or its predecessor (the Scientific Committee on Food, SCF).


In Japan, dietary substances are legally classified as food, food additives, or “non-drug” (food), and are subject to one of two regulations, both enforced by the Ministry of Health, Labor and Welfare (MHLW). CM is categorized as a “non-drug” (MHLW 2009) and is permitted for use as both a food ingredient and a food additive under the Food Sanitation Law (MHLW 2001), allowing it to be imported, distributed, and produced as food in Japan.

New forms of creatine must be approved by the MHLW before they can be imported, distributed, and produced in Japan, one requirement being that sufficient documentation on the safety and similarity to CM must be provided. Currently, two new forms of creatine, CC, and CPY have been approved for import to Japan.

South Korea

In South Korea, the category of dietary supplements was established through legislation in 2004 and is regulated by the Korean Food and Drug Administration (KFDA) (Shimizu 2008). New ingredients must be approved by KFDA and are required to have sufficient toxicological and human clinical trial data supporting the safety and efficacy of the recommended daily dosage. An application for registration of CM was filed with the KFDA in 2005 and was approved for use in dietary supplements in 2008, along with an accompanying health claim (KFDA 2009). At present, no other forms of creatine have been approved for use in South Korea.


In Brazil, nonessential nutrients (such as creatine) are regulated as bioactives or novel food ingredients and must receive approval from the Brazilian National Sanitary Surveillance Agency (or ANVISA) before entering the marketplace (Lajolo and Miyazaki 2007) the approval is based on a comprehensive review of the safety and efficacy of the ingredient and establishes specific requirements for dosage and purity levels, and approved label claims, among other important parameters. ANIVSA recently approved the use of CM in foodstuffs for athletes (reference “Regulations concerning foodstuffs for athletes”. Chapter III, Article 10. The National Health Surveillance Agency Collegiate Board of Directors. 2010). Thus far, Brazil is the only Latin American country to approve the use of creatine and this approval applies specifically to CM.


The legal and regulatory status of CM is unequivocal in the major global markets for dietary or food supplements. The status of other creatine forms present in the marketplace and/or subjected, in the case of the USA, to a pre-market notification is less clear. These alternatives to CM are prevalent in the market, yet do not appear to have met the necessary statutory or regulatory requirements in any of the countries examined. In countries where regulatory approval is required prior to use, with the exception of Japan (CC and CPY), none of these forms has achieved approval. However, it is possible that at the time of this review, additional decisions may be pending by regulatory authorities.

In the USA, a key determinant triggering the need for an NDIN to FDA is whether an NDI which has been present in the food supply has been chemically altered (Federal Food, Drug and Cosmetic Act 1938b). Chemical alteration of an ingredient is presumed to alter its biologic behavior and hence a separate safety assessment is required to establish reasonable expectation of safety or that the altered ingredient is comparable to the native ingredient in relevant characteristics. The various forms listed in Table 2 appear to meet the criteria of being chemically altered, as they appear to be distinct chemical entities (via covalent bonding) versus CM, and thus all are subject to the requisite premarket NDIN to FDA. Only four of the eight forms have been subjected to such a notification and all but one (CPY, no decision to date) have been objected to by FDA. In its responses, the agency has indicated that the form of creatine may not even be a legal dietary ingredient and/or notifiers have failed to establish a reasonable expectation of safety and/or provided inadequate information on the chemical identity of the given creatine form.

Table 2 Global regulatory status for various forms of creatine

Explanations as to why these alternate creatine forms are prevalent in the marketplace despite not having met the legal and regulatory requirements in the various markets are likely two-fold. Legal definitions of and regulatory requirements for “dietary supplements” (USA and Korea), “food supplements” (EU), “natural health products” (Canada), and “non-drug food additives” (Japan) are complex, differ between countries/regions, and can be confusing. Lack of awareness and/or understanding of the given country’s applicable requirements may be one explanation for the lack of compliance on the part of some marketers. To the extent that the laws and regulations are known and understood, inadequate enforcement by regulators can create an environment where noncompliance is perceived to be without consequences, resulting in the forgoing of required registration or notification requirements. In the USA, the increased prevalence of these alternate forms (CEE in particular) in dietary supplement products, with no enforcement action from FDA, has helped to support this misperception.

The public health implications of having unsanctioned or unapproved forms of creatine on the market remain to be fully realized. While classical animal toxicity data (Mertschenk et al. 2001) and short- and long-term clinical safety studies have been conducted in humans (Kreider et al. 2003a; Schilling et al. 2001; Poortmans and Francaux 1999; Dalbo et al. 2008), the basic safety data on new forms of creatine is lacking. At present, there do not appear to be any imminent or specific safety concerns associated with any of these alternate forms. However, this must be monitored carefully through post-market surveillance and published case reports. As far as the marketplace is concerned, the presence of these newer and typically more expensive forms of creatine in a multitude of consumer products that are often marketed with misleading and/or unsubstantiated claims of greater bioavailability, efficacy, and safety sets a negative precedent. The reality that companies need not fulfill the necessary registration or notification requirements to satisfy regulatory authorities, but still feel free to market their ingredients/products without penalty establishes an “unlevel” playing field among competitors. This undermines any incentive to invest upfront resources to establish ingredients as safe and efficacious prior to reaching consumers. Inevitably, this will result in unintended and unforeseen consequences, which will serve to erode consumer confidence.


Creatine monohydrate supplementation has been consistently reported in the literature to increase muscle phosphagen levels, improve repetitive high-intensity exercise performance, and promote greater training adaptations. Moreover, it has been found to be a stable form of creatine that is not significantly degraded during the digestive process and either taken up by muscle or eliminated in the urine. No medically significant side effects have been reported from CM supplementation despite the widespread worldwide use and the regulatory status of CM not being well established. Conversely, the efficacy, safety, and regulatory status of most of the newer forms of creatine found in dietary supplements have not been well established. Additionally, there is little to no evidence supporting marketing claims that these newer forms of creatine are more stable, digested faster, and more effective in increasing muscle creatine levels and/or associated with fewer side effects than CM.